AIMD Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions has a net margin of -3093.98% compared to Ainos's net margin of -348.97%. Ainos's return on equity of -82.37% beat Intelligent Bio Solutions's return on equity of -149.7%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 528.27%. Given that Intelligent Bio Solutions has higher upside potential than Ainos, analysts believe Intelligent Bio Solutions is more attractive than Ainos.

Ainos has a beta of 2.202, which suggesting that the stock is 120.24% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $106.2K, which are smaller than Intelligent Bio Solutions quarterly revenues of $728.9K. Ainos's net income of -$3.3M is lower than Intelligent Bio Solutions's net income of -$2.5M. Notably, Ainos's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 56.59x versus 2.86x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -3093.98% compared to Ainos's net margin of -63.81%. Ainos's return on equity of -82.37% beat Standard BioTools's return on equity of -26.52%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 126.19%. Given that Standard BioTools has higher upside potential than Ainos, analysts believe Standard BioTools is more attractive than Ainos.

Ainos has a beta of 2.202, which suggesting that the stock is 120.24% more volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $106.2K, which are smaller than Standard BioTools quarterly revenues of $40.8M. Ainos's net income of -$3.3M is higher than Standard BioTools's net income of -$26M. Notably, Ainos's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 56.59x versus 2.32x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -3093.98% compared to Ainos's net margin of -193.13%. Ainos's return on equity of -82.37% beat LENSAR's return on equity of -464.33%.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 20%. Given that LENSAR has higher upside potential than Ainos, analysts believe LENSAR is more attractive than Ainos.

Ainos has a beta of 2.202, which suggesting that the stock is 120.24% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $106.2K, which are smaller than LENSAR quarterly revenues of $14.2M. Ainos's net income of -$3.3M is higher than LENSAR's net income of -$27.3M. Notably, Ainos's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 56.59x versus 2.54x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Movano has a net margin of -3093.98% compared to Ainos's net margin of -14402%. Ainos's return on equity of -82.37% beat Movano's return on equity of --.

Ainos has a consensus price target of --, signalling downside risk potential of --. On the other hand Movano has an analysts' consensus of $30.00 which suggests that it could grow by 4445.46%. Given that Movano has higher upside potential than Ainos, analysts believe Movano is more attractive than Ainos.

Ainos has a beta of 2.202, which suggesting that the stock is 120.24% more volatile than S&P 500. In comparison Movano has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ainos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ainos pays -- of its earnings as a dividend. Movano pays out -- of its earnings as a dividend.

Ainos quarterly revenues are $106.2K, which are larger than Movano quarterly revenues of $50K. Ainos's net income of -$3.3M is higher than Movano's net income of -$7.2M. Notably, Ainos's price-to-earnings ratio is -- while Movano's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ainos is 56.59x versus -- for Movano. Usually stocks with elevated PS ratios are considered overvalued.